BFA Law Sounds Alarm: Critical CAPR Deadline Looms
Capricor Therapeutics Class Action Lawsuit: What Investors Need to Know (Simple Guide)
Breaking News: Lawsuit Filed Against Capricor Therapeutics
A major law firm has announced a class action lawsuit against Capricor Therapeutics (NASDAQ: CAPR). If you bought Capricor stock, this affects you. Here’s everything explained in plain English.
Key Facts at a Glance
| Detail | Information |
|---|---|
| Company | Capricor Therapeutics, Inc. (NASDAQ: CAPR) |
| Law Firm | Bleichmar Fonti & Auld LLP (BFA Law) |
| Lead Plaintiff Deadline | September 28, 2026 |
| Biggest Stock Crash | July 27, 2026 — 64.5% drop in one day |
| Court | U.S. District Court, Southern District of California |
| Case Name | Nkamga v. Capricor Therapeutics, Inc. et al., No. 26-cv-04385 |
Who Is Capricor Therapeutics?
Capricor is a biotechnology company — think of them as a science-focused business developing new medicines.
Their main product: Deramiocel — an experimental cell therapy for Duchenne muscular dystrophy (DMD), a rare and serious muscle-wasting disease that mostly affects boys.
ELI5: Imagine a company trying to build a special "repair kit" for damaged muscles. That’s what Deramiocel aims to be.
Why Is There a Lawsuit?
The Short Version
Investors claim Capricor misled them about how well their medicine worked — and the stock crashed when the truth came out.
The Detailed Timeline
1. Late 2024 — Capricor Submits Application to FDA
Capricor asked the FDA (Food and Drug Administration) to approve Deramiocel. This formal request is called a Biologics License Application (BLA).
2. July 2025 — FDA Says "Not Good Enough"
The FDA sent a Complete Response Letter — basically a rejection letter saying:
- The evidence wasn’t strong enough
- More clinical data was needed
3. The Alleged Problem
The lawsuit claims Capricor changed the rules of the game after seeing the data:
- They modified their statistical analysis plan (the math rules for measuring if the drug works)
- The FDA never agreed to these changes
- Capricor didn’t tell investors about this
4. July 27, 2026 — The Bombshell
The FDA released briefing documents before an advisory meeting. These documents revealed:
- Capricor made post-hoc changes (changes after the fact) to how they calculated the main measure of success (called PUL 2.0)
- Changes happened right before the data was unlocked and unblinded
Result: Stock plunged $12.70 per share (64.5%) — from $19.70 to $7.00 in one day.
5. July 29–30, 2026 — Advisory Committee Votes Against Capricor
- FDA advisors met July 29
- July 30: Medscape reported a 9–3 vote that evidence did NOT support Deramiocel’s effectiveness
- Stock dropped another 36% — from $6.57 to $4.19
What Should You Do If You Own(ed) Capricor Stock?
Step-by-Step Action Plan
- Check your records — Did you buy CAPR stock between the relevant dates?
- Visit the case page — https://www.bfalaw.com/cases/capricor-class-action-lawsuit
- Submit your information — Free, no obligation
- Decide if you want to be "Lead Plaintiff" — Deadline: September 28, 2026
IMPORTANT: No Cost to You
- Contingency fee basis — lawyers only get paid if you win
- Zero out-of-pocket costs — no court fees, no expenses
- Court must approve any lawyer fees
Why Bleichmar Fonti & Auld LLP (BFA Law)?
They’re not just any law firm — they’re heavy hitters in securities litigation:
| Recognition | Details |
|---|---|
| Chambers USA | Top plaintiff law firm |
| The Legal 500 | Most client satisfaction awards in the field |
| National Law Journal | "Elite Trial Lawyers" |
| Law360 | "Titans of the Plaintiffs’ Bar" |
| Lawdragon | Top 500 Leading Plaintiff Financial Lawyers |
Recent Big Wins:
- $900+ million from Tesla’s Board of Directors
- $420 million from Teva Pharmaceuticals
Client Testimonial: "There isn’t a better firm in this space. Nimble, entrepreneurial, relentless focus on adding value."
Summary: The Big Picture
| What Happened | Why It Matters |
|---|---|
| Capricor sought FDA approval for Deramiocel | Investors bought stock hoping for approval |
| FDA rejected initial application (July 2025) | Company needed more/better data |
| Capricor allegedly changed analysis rules secretly | This may have made results look better than reality |
| FDA exposed changes in July 2026 documents | Truth came out → stock crashed 64.5% |
| Advisory committee voted 9–3 against efficacy | Second crash: 36% more loss |
| Class action filed for securities fraud | Investors may recover losses |
Bottom line: If Capricor hid important information that would have changed your investment decision, you may have a legal claim.
FAQ: Your Questions Answered
1. What is a "class action" lawsuit?
A class action lets many people with similar claims join together in one lawsuit. Instead of suing individually, one or a few "lead plaintiffs" represent everyone.
2. What is a "Lead Plaintiff" and should I be one?
The Lead Plaintiff is the main representative of the class. They work closely with lawyers and make key decisions. Deadline to apply: September 28, 2026. You don’t have to be Lead Plaintiff to get money if the case wins.
3. How much does this cost me?
$0. Lawyers work on contingency — they only get paid a percentage if the case wins or settles. The court approves all fees.
4. I sold my Capricor stock already. Can I still join?
Yes. If you bought during the "class period" (dates defined by the court) and lost money, you may qualify — even if you sold.
5. How long will this take?
Securities class actions typically take 2–4 years. But you don’t need to do anything after signing up — the lawyers handle the work.
Take Action Now
Submit your info for free:
https://www.bfalaw.com/cases/capricor-class-action-lawsuit
Contact:
Adam McCall
adam@bfalaw.com
212.789.3619
Disclaimer: This article summarizes a press release from Bleichmar Fonti & Auld LLP. It is not legal advice. Past results do not guarantee future outcomes. Attorney advertising.